Guth-Tougelidis B, Müller S, Mehdorn M M, Knust E J, Dutschka K, Reiners C
Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Essen, FRG.
Nuklearmedizin. 1995 Apr;34(2):71-5.
DL-3-123I-iodo-alpha-methyltyrosine (123I-IMT) is a radiopharmacon which concentrates in brain tumors and can be employed in SPECT. We performed 20 studies in 16 patients after neurosurgery for malignant brain tumors (localization of the primary tumor by CT/MRI). Tumor/non-tumor ratios (T/NT) were calculated in ROI-technique. In 17 cases there was a recurrence or tumor remnant. 14/17 were detectable by increased uptake (T/NT 1.43-2.25). The scans were correlated with CT/MRI studies and validated by biopsy (6/14) or follow-up. All 3 patients without recurrence (neuroradiological follow-up over 6-24 months) had a negative scan. 123I-IMT scintigraphy provides complementary information to CT and MRI. In equivocal neuroradiological or clinical cases it may be valuable in the detection of tumor recurrences and allows an earlier onset of therapy.
DL-3-123I-碘-α-甲基酪氨酸（123I-IMT）是一种放射性药物，可在脑肿瘤中聚集，可用于单光子发射计算机断层显像（SPECT）。我们对16例恶性脑肿瘤患者进行了神经外科手术后的20项研究（通过CT/MRI对原发性肿瘤进行定位）。采用感兴趣区（ROI）技术计算肿瘤/非肿瘤比值（T/NT）。17例存在复发或肿瘤残留。其中14/17例可通过摄取增加检测到（T/NT为1.43 - 2.25）。扫描结果与CT/MRI研究进行了对比，并通过活检（6/14）或随访进行了验证。所有3例无复发的患者（神经放射学随访6 - 24个月）扫描结果均为阴性。123I-IMT闪烁扫描可为CT和MRI提供补充信息。在神经放射学或临床情况不明确的病例中，它可能对检测肿瘤复发有价值，并能使治疗更早开始。
